Wutah dodolan YoY sajrone 12 wulan kepungkur: NeoGenomics, Inc. (NEO)

The last twelve months (LTM) change in trading revenue confirms a steady inflow of funds from clinical demand, and the 11.10 value reflects current dynamics. NeoGenomics, Inc. (NEO) maintains its position through the integration of IT systems and rare tests. Business scaling relies on laboratory automation and data analysis software, which increases margins amid a growing order flow.
NeoGenomics Inc (NEO) - rincian metrik lan laporan keuangan

The implementation of robotics and AI in oncology diagnostics allows NeoGenomics, Inc. (NEO) to scale test volumes, which directly converts into market share expansion. The year-over-year revenue dynamics over the trailing twelve months (TTM) measure the income growth rate over the last four quarters, neutralizing seasonal fluctuations and revealing the actual viability of the business while eliminating the risk of capital stagnation amid a low asset valuation.